Salesforce, Dignity Health and McKesson have exited patient engagement software developer Evariant, which had raised more than $86m pre-acquisition.

The cancer antibody drug conjugate developer secured the return of Boehringer Ingelheim Venture Fund ahead of early clinical trials on its lead candidate.

The round included a $10m investment by Ionis Pharmaceuticals which was provided as part of a collaboration agreement.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Cox Enterprises joined returning investors Hearst and Heritage Group in the medical payment service provider’s latest round, which took its overall funding to more than $50m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Deep Genomics will use the money to advance drug candidates created through its AI drug development model, based on research by Toronto faculty.

Lilly Asia Ventures took part in a series B-plus round that marks the first for biopharmaceutical company Transcenta Holding, formed through the merger of two of the corporate's portfolio companies.

WuXi AppTec and New World Development-backed Adagene has now raised $155m in total, as it takes its first cancer immunotherapy through clinical testing.

Bloomberg Beta-backed Deep Genomics will use the series B funding to advance drug candidates created through its artificial intelligence drug development model.